Therapeutic or Preventive Procedure – Page 6

Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program

4 weeks ago talkbio0Tagged Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy, Nkarta, restructuring

Nkarta, restructuring, Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy

Alcon Secures Control of Aurion Biotech in Strategic Takeover

4 weeks ago talkbio0Tagged Alcon, AURN001, biotech, Bovichtus, Cell Therapy, CEO, corneal endothelial disease, IPO, stake, Surgical Replantation

Alcon, Aurion Biotech, majority stake, CEO replacement, cell therapy, corneal endothelial disease, AURN001, IPO dispute

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR

4 weeks ago talkbio0Tagged Approved, choline, Hyperphagia, Prader-Willi Syndrome, Soleno, Svalbard, United States Food and Drug Administration, Vykat

FDA approval, Vykat XR, Prader-Willi syndrome, hyperphagia, Soleno Therapeutics, diazoxide choline

BioSpace Presents the World Atlas of GLP-1s

4 weeks ago talkbio0Tagged BioSpace, Brazil, Cervical Atlas, China, Eli Lilly, GLP-1s, Glucagon-Like Peptide 1, India, Nordisk, Wegovy, World

Eli Lilly, Wegovy, India, China, BioSpace, World, Cervical Atlas, GLP-1s, Nordisk, Glucagon-Like Peptide 1, Brazil, India

GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?

4 weeks ago talkbio0Tagged Effectiveness, GLP-1s, Glucagon-Like Peptide 1, Industry, Injectables, Manufacture, Market, Oral cavity, Orals, orforglipron, production

Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s

Eyeing precision medicines for ocular diseases, Character clinches $93M

1 month ago talkbio0Tagged Glycogen storage disease type II, Personality Character

Glycogen storage disease type II, Personality Character

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis

1 month ago talkbio0Tagged Apellis, Approved, C3 G, Fabhalta, Kidney Diseases, Novartis, pegcetacoplan, Proteinuria, United States Food and Drug Administration

Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases

Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation

1 month ago talkbio0Tagged aligns, announcement, Benefit, capabilities, commitment, Corporation, domestic pharmaceutical industry, Increased, innovation, Investments, J&J 's, Manufacturing, Surgical construction, trends qualifier, United States

This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.